UNSPSC 51281908: Streptozocin

This classification denotes a nitrosourea compound and antineoplastic antibiotic with the molecular formula C8H15N3O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W494URQ81, chemically known as streptozotocin, pure but generally known as streptozocin, which bears US NIH Compound Identifier 5299. European Medicines Agency schedules Streptozocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10658MIG.

UNSPSC 51281908 Streptozocin is a Commodity-tier code covering a single pharmaceutical product — an injectable chemotherapy agent used primarily in cancer treatment and pancreatic islet cell transplantation. State and local governments procure streptozocin through their health and human services agencies, typically as part of pharmacy benefit programs, employee health plans, and Medicaid formularies. The code sees activity primarily from state health departments and state employee benefit programs that manage pharmacy procurement either directly or through contracted pharmacy benefit managers and pharmaceutical wholesalers.

The Texas Health and Human Services Commission posted a Request for Information (RFI) HHS0017013 in April 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for delivering pharmaceuticals outside traditional pharmacy benefit manager and group purchasing organization channels. This early-stage market intelligence gathering suggests the state is evaluating alternative procurement pathways for pharmaceutical products, including streptozocin and similar specialty drugs, to improve cost management and fulfillment efficiency. No formal solicitations, awarded contracts, or financial commitments are evident in recent state and local records under this code. The lack of active RFPs, RFQs, or ITBs indicates minimal current procurement velocity for streptozocin as a standalone commodity across state and local jurisdictions.